Safety and efficacy of voxelotor in pediatric patients with sickle cell disease aged 4 to 11 years - Estepp - 2022 - Pediatric Blood & Cancer - Wiley Online Library
GBT Announces Plans to Seek Regulatory Approval for Oxbryta® (Voxelotor) to Treat Sickle Cell Patients in Europe – TIF
Oxbryta (voxelotor) dosing, indications, interactions, adverse effects, and more
Voxelotor for the Treatment of Sickle Cell Disease - ScienceDirect
Voxelotor | C19H19N3O3 - PubChem
Voxelotor for Treating Sickle Cell Disease: Leveraging Dose Prediction Model for DDI Prediction Without Any Clinical Studies | Certara
EHA Library - The official digital education library of European Hematology Association (EHA)
Daily Medication Pearl: Voxelotor (Oxbryta)
Oxbryta (voxelotor)- Sickle cell disease- by Saro Arakelians, PharmD- Episode #29 - YouTube
EHA Library - The official digital education library of European Hematology Association (EHA)
A Gram-Daily Aldehyde for Anemia: Voxelotor - Drug Hunter
Pharmacokinetics and pharmacodynamics of voxelotor (GBT440) in healthy adults and patients with sickle cell disease - Hutchaleelaha - 2019 - British Journal of Clinical Pharmacology - Wiley Online Library
GBT heads to FDA with sickle cell drug voxelotor | pharmaphorum
Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Haematology
Voxelotor recommended dosage for concomitant medications. | Download Scientific Diagram
TEAEs occurring in >1 healthy volunteer receiving 15 days of voxelotor... | Download Scientific Diagram
FDA Lowers Age Indication for Oxbryta to Treat Younger Children With Sickle Cell Disease - Pharmacy Practice News
Model‐informed drug development of voxelotor in sickle cell disease: Exposure‐response analysis to support dosing and confirm mechanism of action - Green - 2022 - CPT: Pharmacometrics & Systems Pharmacology - Wiley Online Library
A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease | NEJM
Oxbryta (voxelotor) - Rare Disease Advisor
:max_bytes(150000):strip_icc()/VWH_Illustration_Drug_Oxbryta-Voxelotor_Zoe-Hansen_Final-f9a39b42cd2349978ba82cd69393ac57.jpg "Oxbryta (Voxelotor) - Oral: Uses, Side Effects, Dosages, Interactions")
Oxbryta (Voxelotor) - Oral: Uses, Side Effects, Dosages, Interactions
Oxbryta Approval Expanded to Younger Patients With Sickle Cell Disease
PDL DRUG REVIEW
Voxelotor Increases Hemoglobin, Reduces Anemia in SCD, Early Trial Results Show
Taking Oxbryta
